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In patients suffering from heart	 failure	 (HF),	 autonomic	 imbalance	 develops	 even	 at	 early	
stages	 along	 with	 derangements	 of	 cardiopulmonary	 reflex	 control	 and	 abnormalities	
in	 metabolism	 of	 several	 hormones.	 In	 34	 men	 with	 stable	 systolic	 HF,	 we	 investigated	
hypercapnic	chemosensitivity	(HCS,	liter/min·mm	Hg)	measured	using	the	rebreathing	method	
and	 defined	 as	 the	 slope	 of	 the	 regression	 line	 relating	minute	 ventilation	 (VE,	 liter/min)	
to	end­tidal	carbon	dioxide	concentration	(PETCO
2
,	mm	Hg).	Serum	levels	of	testosterone,	
dehydroepiandrosterone	 sulfate,	 type­1	 insulin­like	 growth	 factor	 (IGF­1),	 sex	 hormone­
binding	 globulin	 (SHBG),	 estradiol,	 and	 cortisol	were	measured	 using	 immunoassays.	We	
found	that	 there	were	no	associations	between	HCS	and	clinical	variables,	applied	therapy,	
and	 co­morbidities	 (all	 P >	 0.2).	Augmented	 HCS	 was	 accompanied	 by	 increased	 serum	
SHBG	(when	expressed	in	nM,	r	=	0.43,	P <	0.05;	when	expressed	as	percentage	of	the	age­
matched	reference	values,	r	=	0.62,	P <	0.001)	and	the	reduced	serum	IGF­1	(when	expressed	
in	 ng/ml	 and	 as	 percentage	 of	 the	 above­mentioned	 values,	 r	 =	 –0.49,	P <	 0.05,	 and	 r	 =	 
=	–0.47,	P =	0.007,	respectively).	The	HCS	was	not	related	to	serum	levels	of	all	the	remaining	
analyzed	 hormones	 (all	P >	 0.2).	Thus,	 it	may	 be	 suggested	 that	 the	 hormone	 stimuli	 can	
noticeably	modify	the	reflex	mechanisms	in	cardiorespiratory	control	in	the	clinical	setting	
of	cardiovascular	pathology.
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INTRODUCTION
The complex pathophysiology of systolic heart 
failure	 (HF)	 involves,	 in	 addition	 to	 hemodynamic	
abnormalities,	 the	 dysfunction	 of	 most	 body	 organs,	
including the autonomic nervous and endocrine systems 
[1,	2].	Augmented	hypercapnic	chemosensitivity	(HCS)	
reflects	considerably	deranged	cardiopulmonary	reflex	
control	[3,	4]	manifested,	in	particular,	in	patients	with	
HF	 [2,	 5,	 6].	 This	 phenomenon	 is	 linked	 to	 exercise	
intolerance and poor outcome and mostly occurs at 
early	stages	of	HF	[2,	5,	7].
Men	 with	 systolic	 HF	 are	 characterized	 by	
derangements within the functioning of several 
endocrine	glands	[8]	and	demonstrate	deficiencies	in,	
e.g.,	circulating	testosterone,	dehydroepiandrosterone	
sulfate	(DHEAS),	and	insulin­like	growth	factor	type	1	 
(IGF­1),	 which,	 independently	 of	 each	 other	 and	 of	
other	 clinical	 prognosticators,	 unfavorably	 affect	 the	
long­term	 prognosis	 [9].	 A	 reduced	 level	 of	 serum	
testosterone is related to a diminished lean tissue 
mass	[10],	severe	depressive	symptoms	[11],	exercise	
intolerance	[12,	13],	and	anemia	[14].	Moreover,	IGF­1	 
deficiency in this group of patients is associated with 
further	 reduction	 in	 both	 exercise	 capacity	 [12]	 and	
hemoglobin	 level	 [14],	 whereas	 DHEAS	 deficiency	
is	 linked	with	 augmented	 depressive	 symptoms	 [15].	
We	 have	 also	 demonstrated	 that	 both	 low	 and	 high	
circulating	estradiol	(E
2
)	levels	are	related	to	increased	
mortality	in	men	with	systolic	HF,	which	may	suggest	
that some optimum E
2
 levels are advantageous for 
these	patients	[16].
The autonomic nervous and endocrine systems are 
tightly linked to each other due to the anatomical 
contiguity of the hypothalamic–hypophyseal–
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endocrine	 gland	 axis	 and	 CNS	 structures	 [17].	
Sympathetic	 and	 parasympathetic	 neurons	 within	
both	 central	 and	 peripheral	 nervous	 systems	 are	
characterized	 by	 the	 presence	 of	 receptors	 specific	
for	 androgens,	 estrogens,	 mineralocorticoids,	 and	
glucocorticoids	 [17,	 18].	 On	 the	 other	 hand,	 both	
gonads	and	adrenal	glands	are	innervated	by	autonomic	
nerve	fibers	[19].
Hence,	 taking	 into	 consideration	 these	 close	
interplays	 between	 the	 hormonal	 and	 autonomic	
nervous	 mechanisms	 [17,	 20]	 and	 experimental	
evidence	 that,	 e.g.,	 estrogens	 modulate	 the	 central	
autonomic	 balance	 [21],	 we	 hypothesized	 that	 there	
would	 be	 associations	 between	 the	 hormone	 status	
(assessed	 based	 on	 circulating	 levels	 of	 certain	
hormones)	and	central	HCS	(reflecting	the	efficiency	
of	 reflex	control	of	 respiration).	This	hypothesis	was	
tested on the patients with systolic HF at the early 
stage	of	heart	disease.
METHODS
Examined Group. The recruitment phase of the 
study	was	conducted	in	the	Center	for	Heart	Diseases,	
Military	 Hospital	 (Wroclaw,	 Poland)	 among	 patients	
with	systolic	HF	attending	the	outpatient	HF	clinic.
The	 criteria	 for	 study	 inclusion	 were:	 (i)	 age	
between	 18	 and	 75	 years,	 (ii)	 male	 gender,	 (iii)	 a	
documented	 history	 of	 HF	 for	 more	 than	 6	 months	
preceding	the	study,	(iv)	HF	symptoms	corresponding	
to	 the	 functional	 class	 (New	York	Heart	Association,	
NYHA)	 I­II,	 (v)	 clinical	 stability	 (i.e.,	 unchanged	
severity of the signs and symptoms of HF along 
with	unchanged	medications)	 for	minimum	3	months	
preceding	 the	study,	and	 (vi)	 left	ventricular	ejection	
fraction	(LVEF)	≤45%.
The	 exclusion	 criteria	 were	 as	 follows:	 (i)	 acute	
coronary	syndrome	and/or	coronary	revascularization	
within	 3	 months	 preceding	 the	 study,	 (ii)	 unplanned	
hospitalization	 due	 to	 HF	 deterioration	 or	 any	 other	
cardiovascular	 reason	within	 3	months	 preceding	 the	
study,	 (iii)	 atrial	 fibrillation,	 a	 pacemaker	 rhythm,	
and/or	 frequent	 ectopics,	 and	 (iv)	 any	 hormonal	
dysfunction	 and/or	 hormonal	 therapy	 (either	 in	 the	
time	of	the	study	or	in	the	past).
The	study	protocol	was	approved	by	the	local	Ethics	
Committees,	 and	 all	 subjects	 gave	 written	 informed	
consent.	The	study	was	conducted	in	accordance	with	
the	Helsinki	Declaration.
Study Protocol. In	 all	 patients,	 venous	 blood	
samples were taken in the morning after a supine rest 
of	at	least	15	min.	After	centrifugation,	the	serum	was	
collected	and	frozen	at	–70°C	until	further	analyzed.
The	serum	levels	of	 total	 testosterone	(TT,	ng/ml),	 
DHEAS	 (ng/ml),	 E
2
	 (pg/ml),	 sex	 hormone­binding	
globulin	 (SHBG,	 nM),	 and	 cortisol	 (nM)	 were	
assessed	 using	 electrochemiluminescence	 techniques	
(Elecsys	 2010,	 Roche	 Diagnostics,	 Germany).	 The	
serum	 IGF­1	 level	 (ng/ml)	 was	 assessed	 using	 an	
immunochemiluminescence	 technique	 (Immulite	
2000/2500,	Diagnostic	Products,	USA).
The	 inter­	 and	 intraassay	 variability	 coefficients	
for	TT,	DHEAS,	E
2
,	SHBG,	cortisol,	and	IGF­1	were	
taken	as	3	and	4%,	2	and	4%,	5	and	4%,	2	and	4%,	1	
and	2%,	and	3	and	6%,	respectively.
The	 deficiencies	 of	 TT,	 DHEAS,	 and	 IGF­1	 were	
defined prospectively as a serum hormone level less 
than	or	equal	to	the	10th	percentile	calculated	for	the	
equivalent	age	categories	in	the	cohort	of	healthy	men,	
as	 previously	 described	 [9].	 Serum	TT,	DHEAS,	 and	
IGF­1	 were	 referred	 to	 values	 assessed	 among	 the	
population	of	healthy	men	 living	 in	Wroclaw,	Poland	
[9].	Medians	of	the	analyzed	serum	hormone	levels	in	
the	 age	groups	51	 to	60,	 61	 to	70,	 and	older	 than	71	
years	were	as	follows:	TT,	4.20,	3.90,	and	4.40	ng/ml,	
DHEAS,	1648,	989,	and	936	ng/ml,	and	IGF­1,	290.1,	
268.5,	and	229.0	ng/ml	[9].	
According	 to	 DeGroot	 and	 Jameson	 [22],	 the	 E
2
 
excess in men with systolic HF was defined as serum 
E
2
	 ≥	 50	 pg/ml,	 and	 the	 E
2
 deficiency as serum E
2
	 ≤	 
≤	 10	 pg/ml.	 The	 following	 cut­off	 values	 of	 serum	
SHBG	and	cortisol	were	considered	as	excess	of	these	
hormones:	≥50	and	≥700	nM,	respectively	[22].
The	 level	 of	 plasma	 N­terminal	 pro­B­type	
natriuretic	peptide	(NT­proBNP,	pg/ml)	was	measured	
using	 an	 electrochemiluminescence	 technique	
(Elecsys	 1010/2010,	 Roche	 Diagnostics,	 Germany).	
The	renal	function	was	assessed	based	on	the	estimated	
glomerular	 filtration	 rate	 (GFR;	 ml/min×1.73	 m2)	
[22].	Serum	high­sensitive	C­reactive	protein	(hsCRP,	 
mg/liter)	 was	 assessed	 using	 immunonephelometry	
(Dade	Behring,	Marburg,	Germany)	[22].
HCS Assessment. The	HCS	assessments	(allowing	
us	to	estimate	the	peculiarities	of	respiration	control)	
were	 carried	 out	 between	 9	 and	 12	 a.m.	 in	 an	 air­
conditioned	 room.	All	 subjects	 were	 asked	 to	 avoid	
strenuous	 physical	 activity	 for	 24	 h	 before	 each	 test	
and	 to	 avoid	 smoking,	 eating,	 or	 consuming	 caffeine	
for	3	h	prior	to	the	study.	The	tests	were	preceded	by	
30	min	of	resting	in	a	quiet	environment.
The	HCS	was	assessed	with	a	re­breathing	method	
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[23,	 24]	 using	 a	 5­liter	 bag	 containing	 almost	 100%	
oxygen	initially	and	room	air	in	the	remaining	volume.	
During	the	entire	test,	minute	ventilation	(VE;	liter/min)	
and	end­tidal	carbon	dioxide	concentration	(PETCO
2
,	
mm	Hg)	were	measured	breath	by	breath	using	the	gas	
exchange	 system	 (BREEZE	 EX,	 Cardiorespiratory	
Diagnostic	 Software	 1991­1996,	 Medical	 Graphics,	
USA).	Subjects	were	wearing	a	nose	clip.	The	test	was	
divided	into	three	parts:	(i)	resting	recording	(3	min),	
(ii)	re­breathing	within	a	closed	circuit	(using	a	5­liter	
bag),	 and	 (iii)	 recovery	 (3	min).	During	 both	 resting	
and	 recovery	 stages,	 subjects	 were	 breathing	 with	
room	air.	At	the	beginning	of	the	second	stage,	subjects	
were	 switched	 unnoticeably	 to	 breathing	 within	 a	
closed	circuit.	During	the	re­breathing	stage,	subjects	
were exhaling CO
2
	 to	 a	 5­liter	 bag,	 which	 resulted	
in a steady increase in the CO
2
 concentration within 
this	bag,	and,	subsequently,	in	inhaling	a	gas	mixture	
with a continuously increasing CO
2
 concentration 
in	 peripheral	 blood.	 As	 a	 consequence,	 hypercapnia	
developed	 in	 the	 subjects,	 which	 in	 turn	 induced	
hyperventilation	 in	 a	 reflex	 manner.	 This	 stage	 was	
stopped	when	a	subject	became	either	breathless	(and	
informed	 the	 staff	by	 tagging	at	 a	 table),	 or	PETCO
2
 
exceeded	 70	 mm	 Hg.	 The	 HCS	 was	 defined	 as	 the	
slope	of	 the	regression	graph	relating	VE	to	PETCO
2	
concentration	measured	during	 the	re­breathing	stage	
of	the	test	(expressed	in	liter/min·mm	Hg)	[23,	24].
Statistical Analyses. Normally	 distributed	
continuous	 variables	were	 presented	 as	means	 ±	 s.d.	
The intergroup differences were tested using the 
Student’s	 t­test.	Variables	with	 a	 skewed	distribution	
were expressed as medians with lower and upper 
quartiles	 and	 were	 log­transformed,	 which	 enabled	
normalization	 of	 these	 distributions.	 Categorical	
variables	were	expressed	as	numbers	with	percentages.	
Intergroup differences were tested using the c2	 test.	
Relationships	 between	 continuous	 variables	 were	
calculated	using	 the	Pearson’s	 correlation	coefficient	
for	 variables	 with	 a	 normal	 distribution	 or	 the	
Spearman’s	 rank	 correlation	 coefficient	 for	 variables	
with	a	skewed	distribution.
In	intergroup	comparisons,	values	of	P <	0.05	were	
considered	significant.
RESULTS
Baseline	 clinical	 and	 laboratory	 parameters	 are	
shown	 in	 Table	 1.	 Mean	 values	 of	 the	 serum	 levels	
of	 analyzed	 hormones	 along	 with	 the	 prevalence	 of	
Table 1. Baseline Clinical and Laboratory Characteristics of 
Examined Patients with Mild Systolic Heart Failure (HF)
Т а б л и ц я 1. Вихідні клінічні та лабораторні 
характеристики досліджених пацієнтів з помірною 
систолічною серцевою недостатністю
Conditions for examination of 
patients with mild systolic HF Variables
Inclusion criteria
Age	 	61	±	10	years
BMI 28.6	±	4.0	kg/m2
NYHA	class	I/II 21/79%
Etiology	(CAD) 65%
Hypertension	(yes) 62%
DM	(yes) 24%
LVEF	 31	±	7%	
LVEDD 66	±	8	mm
Hemoglobin 14.4	±	0.9	g/dl
hsCRP 1.23	(0.98	–	2.27)	mg/liter
GFR 82.0	±	13.6	ml/min·1.73	m2
Na 141	±	3	mEq/liter
NT­proBNP	 655	(263	–	942)	pg/ml
Treatment
ACE	inhibitor	and/or	ARB 89%
β­Blocker 100%
Aldosterone	antagonist 12%
Loop diuretic 47%
Thiazide	diuretic 35%
Digoxin 24%
Statin 88%
Acetylsalicylic	acid 82%
Footnotes.	Data	are	presented	as	means	±	s.d.,	medians	with	lower	
and	 upper	 quartiles,	 or	 percentage	where	 appropriate.	BMI,	 body	
mass	index;	NYHA,	New	York	Heart	Association;	CAD,	coronary	
artery	disease;	DM,	diabetes mellitus;	LVEF,	left	ventricular	ejection	
fraction;	 LVEDD,	 left	 ventricular	 end­diastolic	 diameter;	 hsCRP,	
high­sensitivity	C­reactive	protein;	GFR,	glomerular	filtration	rate;	
NT­proBNP,	 plasma	 N­terminal	 pro­B­type	 natriuretic	 peptide;	
ACE,	 angiotensin	 converting	 enzyme;	 and	 ARB,	 angiotensin	
receptor	blocker.
hormonal	abnormalities	in	men	with	mild	systolic	HF	
are	shown	in	Table	2.
The	mean	value	of	HCS	in	examined	men	with	mild	
systolic	 HF	 was	 0.68	 (0.43­0.95)	 liter/min·mm	 Hg,	
and was higher than the reference values assessed in 
our	laboratory	(P <	0.01).
There	 were	 no	 associations	 between	 HCS	 and	
clinical	 variables	 (including	 the	 plasma	 NT­proBNP	
level),	 applied	 therapy,	 and	 co­morbidities	 (in	 all	
cases,	P >	0.2).
The	 augmented	 HCS	 was	 accompanied	 by	 an	
increased	serum	SHBG	level,	when	expressed	both	in	
nM	(r	=	0.43,	P <	0.05,	Fig.	2)	and	when	normalized	
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Table 2. Serum Hormone Levels and Frequency of Cases of Hormone Deficiency or Excess in Examined Patients with Mild Systolic 
Heart Failure (HF)
Т а б л и ц я 2. Рівні гормонів у сироватці крові та частота випадків дефіциту або надлишку гормонів у досліджених 
пацієнтів з помірною систолічною серцевою недостатністю  
Analyzed	hormones
Patients	with	mild	systolic	HP	(n	=	34)
mean values of the serum 
hormone levels hormone	deficiency	(%) hormone	excess	(%)
TT 5.00	(4.30	–	5.80)	ng/ml 9 –
DHEAS	 558	(96	–	1214)	pg/ml 47 –
IGF­1	 114.5	(103.0	–	141.0)	ng/ml 91 –
SHBG 46.3	(38.5	–	57.3)	nM – 38
E
2
 29.4	(25.1	–	31.8)	pg/ml 0 0
Cortisol 613	(517	–	718)	nM – 30
Footnotes.	Data	are	presented	as	medians	with	lower	and	upper	quartiles	or	percentages	where	appropriate.	TT,	total	testosterone;	DHEAS,	
dehydroepiandrosterone	sulfate;	IGF­1,	type­1	insulin­like	growth	factor;	SHBG,	sex	hormone	binding	globulin,	and	E
2
,	estradiol.
F i g. 1.	 Relationship	 between	 the	 serum	 level	 
of	 insulin­like	 growth	 factor	 type	 1	 (abscissa,	 
ng/ml)	 and	 hypercapnic	 chemosensitivity	 (ordinate,	 
liter/min·mm	 Hg)	 in	 patients	 with	 mild	 systolic	 
heart	failure.
Р и с. 1.	Взаємовідношення	рівнів	інсуліноподіб-
ного	фактора	росту	типу	1	у	сироватці	крові	(вісь	
абсцис,	нг/мл)	 та	хемочутливості	 до	 гіперкапнії	
(вісь	ординат,	л/хв·мм	рт.	ст.)	у	пацієнтів	з	помір-
ною	систолічною	серцевою	недостатністю.
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with respect to the age-matched reference values 
(r	 =	 0.62,	P <	 0.001),	 and	 the	 reduced	 serum	 IGF­1	
level,	 also	when	 expressed	 in	 both	 ng/ml	 (r	 =	 –0.49,	
P <	 0.05,	 Fig.	 1)	 and	 as	 percentage	 of	 age­matched	
reference	values	(r	=	–0.47,	P =	0.007).	
The	HCS	was	not	related	to	serum	levels	of	all	the	
remaining	analyzed	hormones	(in	all	cases,	P >	0.2).
DISCUSSION
In	our	study,	we	have	demonstrated	that	men	with	mild	
systolic HF treated according to current guidelines 
manifest	 noticeably	 augmented	 central	 hypercapnic	
chemoreceptor	 sensitivity.	 Our	 observation	 confirms	
that reflex mechanisms controlling the functioning 
of the cardiopulmonary system are deranged at early 
stages	of	the	heart	disease,	and	therapies	counteracting	
the overactivated renin-angiotensin-aldosterone and 
adrenergic	systems	do	not	bring	these	mechanisms	to	
normalization	[2].	It	should	be	emphasized	that	we	have	
not found any associations of the chemosensitivity 
with	 any	 clinical	 and	 laboratory	 parameters,	 applied	
treatment,	 and	 co­morbidities	 in	 men	 with	 mild	
systolic	HF.	 In	 particular,	 at	 the	 early	 stage	 of	 heart	
disease,	 augmented	 hypercapnic	 chemoreceptor	
sensitivity	 reflects	 neither	 the	 HF	 severity,	 the	
magnitude	 of	 inflammation	 (expressed	 using	 serum	
hsCRP),	 the	 neurohormonal	 activation	 (measured	
using	plasma	NT­proBNP),	and	the	presence	of	major	
co­morbidities,	such	as	anemia,	renal	dysfunction,	and	
diabetes mellitus.
There	is	evidence	that	androgens	are	responsible	for	
increased	 ventilatory	 force	 in	 men	 [25].	Also,	 in	 an	
experimental	rodent	model	of	cerebral	ischemia,	the	E
2
 
deficiency	was	found	to	be	linked	with	the	autonomic	
imbalance,	 which	 can	 be	 at	 least	 partly	 restored	
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during E
2
	 supplementation	 [21].	 However,	 although	
anticipated	 [25],	 we	 did	 not	 find	 relations	 between	
hypercapnic chemoreceptor sensitivity and circulating 
levels of neither TT nor E
2
.	 In	 this	context,	 it	 is	very	
intriguing	that	we	have	found	the	other	relationships,	
i.e.,	between	augmented	HCS	and	low	IGF­1	together	
with	 high	 SHBG	 levels	 in	 men	 with	 systolic	 HF.	
Although	anticipated,	we	did	not	record	any	relations	
between	 the	 chemosensitivity	 and	 cortisol	 level	 in	
examined	patients.	
Although	 it	 is	not	 commonly	acknowledged,	 IGF­1	 
is an important modulator of the functions of the 
autonomic	nervous	system	[26,	27].	Cachectic	patients	
with	HF,	on	the	one	hand,	develop	abnormal	functioning	
of	 the	 growth	 hormone­IGF­1	 axis	 [28],	 and,	 on	 the	
other	hand,	demonstrate	a	severe	autonomic	imbalance	
and	 overactivation	 of	 central	 chemoreceptors	 [28].	
Moreover,	 we	 showed	 earlier	 that	 men	 with	 systolic	
HF	 along	 with	 IGF­1	 deficiency	 develop	 exercise	
hyperpnea	 [12].	 Therefore,	 the	 relationship	 between	
an overactivated chemoreflex and reduced circulating 
IGF­1	levels	reported	here	might	at	least	partly	explain	
the	previously	observed	phenomena.	
It	should	be	taken	into	account	that	SHBG	not	only	
is	 an	 agent	 responsible	 for	 the	 transport	 of	 steroid	
hormones	 in	 the	 circulation	 but	 also	 is	 considered	 a	
separate	 hormone	 that,	 through	 its	 interaction	 with	
specific	 receptors,	 can	 modify	 the	 metabolism	 of	
target	cells,	including	the	autonomic	structures	within	
the	CNS	[29].	Patients	with	HF	demonstrate	increased	
serum	 levels	 of	 SHBG	 accompanied	 by	 high	 plasma	
NT­proBNP,	 low	 LVEF,	 and	 low	 BMI	 levels	 [30];	
this	constitutes	an	independent	factor	for	unfavorable	
prognosis	 [30].	 In	 other	 clinical	 settings,	 SHBG	
has	 been	 linked	 with	 the	 nutrition	 status,	 metabolic	
syndrome,	 hyperinsulinemia,	 and	 insulin	 resistance	
[31­33].	Our	observations	are	 the	first	report	relating	
the	 circulating	 SHBG	 level	 to	 the	 efficacy	 of	 reflex	
control of cardiorespiratory functioning in the clinical 
setting	 of	 a	 cardiovascular	 disease.	This	 relationship	
may	be	expected	because	the	autonomic	nerve	centers	
reveal	 a	 high	 affinity	 to	 SHBG,	 and	SHBG	has	 been	
shown to modify the functioning of these structures in 
experimental	studies	[29].
Our	 study	 has	 certain	 limitations.	 The	 first	 one	 is	
the	 relatively	 low	number	of	 examined	 subjects	with	
systolic	HF,	which	is	mainly	due	to	the	very	laborious	
and time-consuming character of physiological 
measurements	 (in	 particular,	 that	 of	 HCS).	 Second,	
we would like to point out that we have assessed in 
our	study	the	functioning	of	endocrine	glands	(gonads,	
adrenals)	using	baseline	circulating	levels	of	produced	
and released hormones without the comprehensive 
and dynamic assessment of the entire hypothalamic-
hypophyseal-gonadal and hypothalamic-hypophyseal-
adrenal	 axes.	 We	 believe	 that	 the	 latter	 information	
is	not	obligatory	for	 full	 interpretation	of	 the	results,	
as	 the	 hormone	 parameters	 analyzed	 in	 our	 study	
are considered standard hormone measures used in 
everyday	clinical	practice.
Finally,	we	need	 to	acknowledge	 the	observational	
character	 of	 our	 study,	 as	 we	 have	 not	 assessed	 the	
F i g. 2. Relationship	 between	 the	 serum	 level	 of	
sex	 hormone­binding	 globulin	 (abscissa,	 nM)	 and	
hypercapnic	 chemoreceptor	 sensitivity	 (ordinate,	
liter/min·mm	Hg)	in	patients	with	mild	systolic	heart	
failure.	
Р и с. 2.  Взаємовідношення	 рівнів	 глобуліну,	
що	 зв’язує	 статеві	 гормони	 (вісь	 абсцис,	 нМ),	
та	 хемочутливості	 до	 гіперкапнії	 (вісь	 ординат,	 
л/хв·мм	рт.	ст.)	у	пацієнтів	з	помірною	систолічною	
серцевою	недостатністю.
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precise	 mechanism	 responsible	 for	 the	 observed	
relationships.	 The	 above	 interesting	 and	 intriguing	
results	need	further	experimental	studies.
Thus,	 men	 with	 systolic	 HF	 at	 the	 early	 stage	 of	
heart	 disease	 demonstrate	 augmented	 HCS	 that	 is	
particularly	increased	in	subjects	with	reduced	serum	
IGF­1	and	higher	serum	SHBG	levels.	Thus	suggests	
that some hormones with the respective receptors 
in the autonomic centers may modify the reflex 
mechanisms of cardiorespiratory control in the clinical 
setting	of	 cardiovascular	pathology.	Hence,	modified	
levels	of	SHBG	and	IGF­1	may	be	a	factor	responsible	
for	 augmented	 ventilation	 and	 subjective	 feeling	 of	
dyspnea	in	patients	with	HF.
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Р	е	з	ю	м	е
У	пацієнтів	із	серцевою	недостатністю	(СН)	навіть	на	ран-
ніх	 стадіях	 захворювання	 розвивається	 автономний	 дис-
баланс	 паралельно	 з	 розладами	 контролю	 серцево­судин-
ної	системи	та	відхиленнями	метаболізму	деяких	гормонів	
від	норми.	Ми	досліджували	хемочутливість	до	гіперкапнії	
(HCS)	у	34	чоловіків	із	СН,	використовуючи	метод	зворот-
ного	 дихання.	 Така	 чутливість	 визначалась	 як	 нахил	 лінії	
регресії	 при	 співставленні	 хвилинного	 об’єму	 вентиляції	 
(л/хв)	та	кінцевої	концентрації	двооксиду	вуглецю	(мм	рт.	ст.).	 
Рівні	тестостерону,	дигідроепіандростерону	сульфату,	інсу-
лінподібного	 фактора	 росту	 типу	 1	 (IGF­1),	 глобуліну,	що	
зв’язує	 статеві	 гормони	 (SHBG),	 естрадіолу	 та	 кортизолу	
визначали	в	сироватці	крові,	використовуючи	імунологічні	
методики.	 Як	 виявилося,	 зв’язки	 між	 рівнем	HCS,	 з	 одно-
го	боку,	та	клінічними	показниками,	застосованою	терапією	
та	супутніми	захворюваннями	–	з	другого,	були	відсутніми	
(в	усіх	випадках	P >	0.2).	Підвищена	HCS	супроводжувала-
ся	 підвищеними	 рівнями	SHBG	 (для	 концентрацій	 у	 нано-
молях	на	1	л	 r	=	0.43,	P <	0.05,	а	для	нормованих	значень,	
наведених	щодо	 певної	 вікової	 групи,	 r	 =	 0.62,	P <	 0.001)	
та	 низькими	 рівнями	 IGF­1	 (для	 концентрацій	 у	 наногра-
мах	на	1	мл	та	для	наведених	нормованих	значень	r	=	–0.49,	
P <	0.05	та	r	=	–0.47,	P =	0.007	відповідно).	Значення	HCS 
не	виявляли	будь­яких	зв’язків	з	рівнями	всіх	досліджених	
гормонів	у	сироватці.	Це	дозволяє	думати,	що	гормональні	
стимули	 можуть	 помітно	 модифікувати	 рефлекторні	 меха-
нізми	контролю	серцево­судинної	 системи	у	клінічних	ви-
падках	її	патологій.
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